Silvio Traversa
Chief Tech/Sci/R&D Officer chez SIENNA BIOPHARMACEUTICALS, INC.
Profil
Silvio Traversa is currently the Chief Scientific Officer at Sienna Biopharmaceuticals, Inc. He was previously the Chief Scientific Officer at Creabilis Therapeutics Srl from 2007 to 2016.
Prior to that, he worked as a Principal at.
Industria Farmaceutica Serono SpA.
Traversa received his undergraduate and doctorate degrees from the University of Turin and his graduate degree from Harvard Business School.
Postes actifs de Silvio Traversa
| Sociétés | Poste | Début |
|---|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/12/2016 |
Anciens postes connus de Silvio Traversa
| Sociétés | Poste | Fin |
|---|---|---|
Creabilis Therapeutics Srl
 Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Chief Tech/Sci/R&D Officer | 01/12/2016 |
| Industria Farmaceutica Serono SpA | Corporate Officer/Principal | - |
Formation de Silvio Traversa
| University of Turin | Doctorate Degree |
| Harvard Business School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Industria Farmaceutica Serono SpA | |
Creabilis Therapeutics Srl
Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Health Technology |
